Press Releases

Date Title
09/15/17
Summary ToggleT2 Biosystems Announces Pricing of Public Offering of Common Stock Printer Friendly Version LEXINGTON, Mass. , Sept. 15, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced the pricing of an underwritten registered public offering of 4,375,000 shares of common stock at a public offering price of $4.00 per share, before underwriting discounts, for gross proceeds of
09/14/17
Summary ToggleT2 Biosystems Announces Proposed Public Offering of Common Stock Printer Friendly Version LEXINGTON, Mass. , Sept. 14, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it is commencing an underwritten registered public offering of shares of its common stock. T2 Biosystems also intends to grant the underwriters a 30-day option to purchase up to an
09/11/17
Summary ToggleT2 Biosystems Submits 510(k) Application to the FDA for Review of T2Bacteria Panel Printer Friendly Version T2Bacteria Panel pivotal clinical trial demonstrates highly accurate results with overall average sensitivity of 95.8% and average specificity of 98.1% LEXINGTON, Mass. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative
09/06/17
Summary ToggleT2 Biosystems and Cidara Therapeutics Announce Partnership for Commercial Placement of T2Dx Instruments to Support CD101 Drug Trials Printer Friendly Version Exclusive pricing program designed to drive uptake of T2 Biosystems’ products and accelerate enrollment in Cidara’s CD101 trials, targeting deadly sepsis-causing pathogen Candida LEXINGTON, Mass. and SAN DIEGO , Sept. 06, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), an emerging
09/06/17
Summary ToggleT2 Biosystems Announces Collaboration with CDC to Detect Emerging Superbug Candida auris Printer Friendly Version CDC to Utilize T2Dx Instrument for Testing of Patient Samples and Monitoring Hospital Environments New Application of T2MR Technology for Detection of Candida auris in Patient Skin, Patient Blood and Hospital Environmental Samples Now Available for Investigational Purposes LEXINGTON, Mass. , Sept.
08/30/17
Summary ToggleT2 Biosystems Announces 11 New Patents Granted in 2017 Printer Friendly Version Advances T2 Biosystems’ technological advantage for T2MR platform LEXINGTON, Mass. , Aug. 30, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, announced today that it has been granted 11
08/03/17
Summary ToggleT2 Biosystems Reports Second Quarter 2017 Financial Results; Provides Company Update Printer Friendly Version Sequential Quarterly Product Revenue Growth of 16.5% LEXINGTON, Mass. , Aug. 03, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, announced today operating highlights and financial results
08/02/17
Summary ToggleT2 Biosystems to Present at the 37th Annual Canaccord Genuity Growth Conference Printer Friendly Version LEXINGTON, Mass. , Aug. 02, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that John McDonough , president and chief executive officer, and Darlene Deptula-Hicks , SVP and
07/27/17
Summary ToggleT2 Biosystems Joins Antimicrobials Working Group as First Diagnostic Member Printer Friendly Version LEXINGTON, Mass. , July 27, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, announced today that it will join the Antimicrobials Working Group (AWG) as its first diagnostic member.
07/20/17
Summary ToggleT2 Biosystems Announces 2017 Second Quarter Financial and Operational Results Release and Conference Call Date Printer Friendly Version LEXINGTON, Mass. , July 20, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that it will release its 2017 second quarter financial and operational results after the market